In vitro safety of ketotifen as a topical nasal rinse
BackgroundKetotifen is a second ‐generation noncompetitive H1‐antihistamine and mast‐cell stabilizer. It is commonly used to treat or prevent allergic conjunctivitis, asthma, chronic urticaria, anaphylaxis, mast‐cell, and other allergic‐type disorders. However, it has never been studied in aspirin‐exacerbated respirato ry disease (AERD), an aggressive phenotype of chronic rhinosinusitis with nasal polyps, where the mast cell plays a prominent role its pathogenesis.MethodsHuman sinonasal epithelial cells were grown at an air ‐liquid interface (ALI). Ketotifen powder was dissolved in saline to make 4 test solutions at 1.04, 2.08, 10.4, and 20.8 µg/mL. Control (saline) or ketotifen solution was added apically to ALI cultures from tissue of 5 unique patients, and ciliary beat frequency (CBF) changes were recorded. Lacta te dehydrogenase was measured at 24 and 48 hours to estimate long‐term cellular toxicity.ResultsApical application of ketotifen at all concentrations was neither ciliotoxic nor ciliostimulatory, with no change in CBF over a period of 15 minutes after application. Cellular toxicity for all concentrations at 24 and 48 hours after application was
His group will study how abnormal calcium signals may contribute to human diseases such as allergies and asthma. (read more)
CONCLUSION: Dermatological and psychiatric conditions are frequent and underestimated among medical students in Morocco. Dermatologic and psychiatric comorbidity is associated with a higher prevalence of psychoactive substance use and suicide attempts. PMID: 32473776 [PubMed - as supplied by publisher]
DR MARTIN SKURR: Risk factors for developing a peanut allergy later in life include a history of eczema, or a family or personal history of any allergies.
VERDICT: It is unclear if people with asthma are at increased risk of contracting COVID-19 or of worse outcomes from COVID-19 infection. The evidence available is limited with some sources suggesting an underrepresentation of PWA in hospitalised cases, and others showing an increased risk of worse outcomes in PWA which may be associated with disease severity. Consensus broadly holds that asthma medications should be continued as usual. Asthma care may be disrupted during the pandemic; self-management and remote interventions may be of benefit but have not been tested in this context.
Condition: HIV Intervention: Biological: VRC-HIVMAB0102-00-AB Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Condition: Immunodeficiency Intervention: Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Condition: Asthma Interventions: Drug: CSJ117; Drug: Placebo Sponsor: Novartis Pharmaceuticals Not yet recruiting
Condition: Asthma Attack Intervention: Other: Interview Sponsor: University of Nottingham Not yet recruiting
Authors: Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitzma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J Abstract The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012(1-3). The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses ar...
Asthma can vary greatly from person to person, with differences in severity and frequency of attacks as well as what triggers those attacks.